FDA Issues Warning on Severe Lung Inflammation With CDK4/6 Inhibitors in Breast Cancer
The FDA is updating the prescribing information and Patient Package Insert for CDK4/6 inhibitors to include a warning that the treatments in rare cases may cause severe inflammation of the lungs.
Source: OncLive